Thrivent International Large Cap ETF
TILC - ETF AI Analysis
Top Page
Thrivent International Large Cap ETF (TILC)
TILC’s rating reflects a generally solid mix of high‑quality international large-cap stocks, led by strong holdings like Novartis, which brings robust profitability, a healthy balance sheet, and steady growth potential, and ABB, which adds strong financials and a positive outlook despite a somewhat rich valuation. Other key positions such as ASML and Investor AB also support the fund with solid fundamentals and growth prospects, while some holdings like Shell and BHP introduce more short-term volatility and growth challenges. The main risk is that the fund is concentrated in a relatively small set of large international companies and sectors, so weakness in a few major names or regions could have an outsized impact on performance.
TILC vs. SPDR S&P 500 ETF (SPY)
- AUM
- 888.19M
- Region
- Developed Markets
- Expense Ratio
- 0.52%
- Beta
- 0.60
- Issuer
- Thrivent
- Inception Date
- Jun 15, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TILC Summary
Thrivent International Large Cap ETF (TILC) is an international stock fund that focuses on large, well-established companies outside the U.S., rather than tracking a specific index. It spreads investments across many countries like Japan, the UK, and France, and across sectors such as financials, industrials, and health care. Well-known holdings include ASML Holding and Novartis. Someone might invest in TILC to diversify beyond U.S. stocks and tap into long-term growth in developed markets overseas. A key risk is that the fund’s value can rise or fall with global markets and foreign currency swings.
How much will it cost me?
This ETF has an expense ratio of 0.52%, which means you’ll pay about $5.20 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because this fund is actively managed, which typically involves more research and trading.
What would affect this ETF?
This ETF could benefit if developed markets outside the U.S. grow steadily, especially in areas like technology, health care, and industrials where top holdings such as ASML, Novartis, and ABB operate, and if global trade and energy demand support companies like BHP and Shell. On the other hand, slower economic growth abroad, rising interest rates that pressure financial firms like Allianz and BNP Paribas, currency swings, or geopolitical tensions in Europe or Asia could hurt returns for this international large-cap fund.
TILC Top 10 Holdings
TILC leans heavily on Europe and other developed markets outside the U.S., with a clear tilt toward healthcare, industrials, and financials. Drugmakers Novartis and Roche have been steady climbers, giving the fund a healthy backbone, while Shell’s strong run in energy has added extra fuel to returns. On the flip side, ASML has lost some near-term momentum, and banks like BNP Paribas and NatWest have been lagging, acting as a brake. Overall, the fund is diversified across sectors and countries, but a few big names are clearly steering the ride.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 3.07% | $29.06M | EUR 511.40B | 51.88% | 76Outperform | |
| Novartis AG | 2.49% | $23.53M | CHF 245.40B | 26.78% | 80Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| Shell (UK) | 1.88% | $17.76M | GBP 210.62B | 30.08% | 73Outperform | |
| BHP Group Ltd | 1.75% | $16.54M | AUD 299.21B | 35.84% | 68Neutral | |
| BNP Paribas | 1.54% | $14.53M | EUR 105.57B | 37.33% | 77Outperform | |
| Investor AB | 1.47% | $13.89M | SEK 1.33T | 36.07% | 77Outperform | |
| Sanofi | 1.41% | $13.36M | EUR 105.08B | -3.14% | 75Outperform | |
| GlaxoSmithKline | 1.37% | $12.92M | GBP 76.63B | 5.58% | 77Outperform | |
| NatWest Group | 1.21% | $11.48M | GBP 47.34B | -3.72% | 75Outperform |
TILC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TILC, the sentiment is Positive. The current price of 24.98 is above the 20-day moving average (MA) of 24.86, below the 50-day MA of 25.11, and compared to the 200-day MA of , indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 50.70 is Neutral, neither overbought nor oversold. The STOCH value of 46.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TILC.
TILC Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $24.98 | $27.00(8.10% Upside) | $888.19M | 0.52% | 63Neutral | |
| $39.81 | $43.29(8.74% Upside) | $753.71M | 0.59% | 62Neutral | |
| $35.54 | $39.36(10.76% Upside) | $604.18M | 0.65% | 65Neutral | |
| $79.67 | $90.59(13.71% Upside) | $377.10M | 0.23% | 65Neutral | |
| $71.96 | $83.13(15.52% Upside) | $241.01M | 0.30% | 62Neutral | |
| $28.72 | $32.52(13.23% Upside) | $118.31M | 0.37% | 61Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TILC | Thrivent International Large Cap ETF | 24.98 | -0.37 | -1.45% | |
| FYLD | Cambria Foreign Shareholder Yield ETF | 39.81 | 9.12 | 29.73% | |
| TXUE | Thornburg International Equity ETF | 35.54 | 5.39 | 17.89% | |
| AVSD | Avantis Responsible International Equity ETF | 79.67 | 10.40 | 15.01% | |
| DXIV | Dimensional International Vector Equity ETF | 71.96 | 11.66 | 19.35% | |
| TLCI | Touchstone International Equity ETF | 28.72 | 3.32 | 13.07% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
